Remember when everyone was freaking out about AI taking over the world? Well, tech stocks got so beaten down in Q1 that they're now cheaper than they were *before* ChatGPT showed up and changed everything. If that's not a "buy the dip" signal, I don't know what is. Here's the deal: Tech valuations have compressed from 40x earnings down to 20x—basically back to 2022 levels. The Iran War, market jitters, and general tech sector pessimism have created what Futurum CEO Daniel Newman is calling a "historically opportune moment" to jump back in. Translation: prices are stupid cheap right now. The ...

Goldman Sachs just reported Q1 earnings this morning. JPMorgan, Citi, and Wells Fargo follow tomorrow. Bank of America and Morgan Stanley hit Wednesday. This is the week where the biggest financial institutions in the world show their hand — and right now, most of them are trading at lower valuations than they were at the end of 2025, even as earnings estimates have actually gone up. That combination — lower price, higher expected earnings — is the textbook definition of a better deal. Forward price-to-earnings ratios across the major banks have compressed meaningfully in recent months, drive...

Everyone bought the drone stocks. Now there's a smarter play hiding in plain sight — the companies building systems to shoot them down. The Iran conflict has turbocharged what was already one of defense's fastest-growing niches: counter-unmanned aircraft systems, or counter-UAS. The counterdrone market currently sits at roughly $6.6 billion. Analysts project it will reach $20 billion by 2030 — a compound annual growth rate of about 25%. That's not speculation; that's a market where demand is already flooding in from three separate channels simultaneously: military operations, homeland securit...

Nike insiders just made a major purchase after a 75% collapse in the stock price. And a director at ThredUp — a fast-growing online resale platform — just put real money down for the first time. When insiders move in silence, it's worth paying attention. Start with Nike (NKE). Under former CEO John Donahoe, the brand executed one of the worst retail pivots in modern memory: pulling from physical stores, leaning on recycled classics like Dunks and Air Jordans, and bleeding customers to upstarts like Hoka and On Running. The damage? A 75% collapse in share prices since 2021. New CEO Elliott Hil...

Here's the thing about AI IPOs that nobody's talking about: the real money gets made before the stock ticker even starts moving. Right now, OpenAI, SpaceX, Anthropic, and Anduril are still private. You know, the companies actually *building* the AI that's reshaping the world. Meanwhile, most retail investors are stuck buying Nvidia chips and Microsoft cloud services—basically the financial equivalent of selling shovels during a gold rush instead of mining the gold yourself. But 2026 is about to change that game completely. **The Trillion-Dollar Lineup** OpenAI's heading for an IPO that cou...

So here's the thing about geopolitics and your stock portfolio: they're basically dating, and right now they're having a really messy breakup. Over the weekend, VP JD Vance jetted off to Pakistan to smooth things over between the US and Iran. Spoiler alert: it didn't work. After nearly 24 hours of talks that apparently went nowhere, Trump responded the way Trump responds to everything—with a Truth Social post announcing a full blockade of the Strait of Hormuz. Because nothing says "let's negotiate" like threatening to shut down one of the world's most critical shipping routes. The market's r...

Q1 2026 was a rough quarter. The S&P 500 dropped 4.33%, Middle East tensions hammered energy prices, AI fears sparked a "SaaS-pocalypse," and private credit markets were rattled enough that most BDCs restricted redemptions. Against that backdrop, Royalty Pharma (NASDAQ: RPRX) gained 25.6%. That kind of divergence doesn't happen by accident. Patient Capital Management, a Baltimore-based value shop, called RPRX its top Q1 contributor in its recently published investor letter. The core of their argument: Royalty Pharma is the world's largest buyer of biopharmaceutical royalties, and the busi...

Eric Fry made his name in the early 2000s by doing something that felt crazy at the time: walking away from the hottest tech stocks at the peak of the dot-com boom and buying the boring stuff instead. Hotels. Copper miners. Fashion houses. It worked spectacularly. Now he's running the same play — this time against AI. Fry's thesis, laid out in his Smart Money column this week, isn't that AI is dead. Far from it. His argument is subtler and more historically grounded: at the peak of every dominant tech wave, the best returns don't come from the dominant technology — they come from the companie...

Here's a strange thing happening in financial markets right now: oil just blew past $100 a barrel, the U.S. is blockading the Strait of Hormuz, and stocks are barely flinching. If that feels counterintuitive, you're reading the market correctly — because it is. U.S. crude futures jumped more than 8% Monday to $104.93 a barrel after President Trump announced a naval blockade of the Strait of Hormuz following the weekend collapse of U.S.-Iran nuclear talks. Brent wasn't far behind, clearing $102. Energy sector ETFs are among the biggest winners year-to-date — up roughly 23% — while the broader ...

Novo Nordisk (NVO) is up 3.6% today after announcing a $2.6 billion partnership with Aspect Biosystems, and honestly? This could be the real deal—or it could be pharmaceutical theater. Let's break it down. Here's the situation: Novo Nordisk is the company behind Ozempic and Wegovy, those weight-loss drugs everyone's been talking about. They've basically printed money off semaglutide, raking in $25 billion in revenue in 2022 alone. But here's the thing about blockbuster drugs—they eventually hit a ceiling. So the company's doing what smart pharma companies do: they're building a pipeline. Ent...